David Goldstein

31k citations
391 papers · 23.1k · 6 hit papers · h-index 67

Impact in

  • Oncology top 0.05%
    • Pancreatic and Hepatic Oncology Research
    • Cancer Treatment and Pharmacology
    • Cancer survivorship and care
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Gastrointestinal Tumor Research and Treatment

Papers in

    • Pancreatic and Hepatic Oncology Research 94
    • Cancer Treatment and Pharmacology 59
    • Cancer survivorship and care 34
    • Colorectal Cancer Treatments and Studies 17
    • Gastrointestinal Tumor Research and Treatment 18

David Goldstein

380 papers receiving 22.4k citations

David Goldstein's Hit Papers

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial 2018 · 1.1k citations
1.1k0+6+12Years since publication1k2k3k

Peers

David Goldstein
Comparison fields: 5 of 165
  • Oncology 13.5k
  • Gastroenterology 648
  • Cancer Research 908
  • Pulmonary and Respiratory Medicine 1.6k
  • General Health Professions 1.1k
Replace Anna Gavin with:
Anna Gavin United Kingdom
Winette T. A van der Graaf Netherlands
ALFRED W. RADEMAKER United States
David Osoba Canada
Gemma Gatta Italy
Judy Ellen Garber United States
Lynn A. G. Ries United States
Sabine Siesling Netherlands
Valter Torri Italy
David P. Ryan United States
David Goldstein relative to Anna Gavin United Kingdom Anna Gavin's profile →
Citations per field
00.5×2×4×5.5×
Anna Gavin · 1×
Citations per year

Countries citing papers authored by David Goldstein

Since Specialization
Citations

This map shows the geographic impact of David Goldstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Goldstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Goldstein more than expected).

Fields of papers citing papers by David Goldstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Goldstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Goldstein. The network helps show where David Goldstein may publish in the future.

Co-authors

The 25 scholars most cited alongside David Goldstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Goldstein Line = papers co-authored together David Goldstein links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 391 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Hit paper breakdown →
20073124
2
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
Hit paper breakdown →
20101106
3
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Hit paper breakdown →
20181060
4
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
Hit paper breakdown →
2016827
5
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Hit paper breakdown →
2013614
6
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
Hit paper breakdown →
2015565
7 2004519
8 2004434
9 2008413
10 2014347
11 2010304
12 2018295
13 2005238
14 2005217
15 2017215
16 2011211
17 2009210
18 2017210
19 2017200
20 2008187

About David Goldstein

David Goldstein is a scholar working on Oncology, Gastroenterology, General Health Professions, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health, having authored 391 papers that have together received 23.1k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (94 papers), Cancer Treatment and Pharmacology (59 papers), Cancer survivorship and care (34 papers), Gastrointestinal Tumor Research and Treatment (18 papers), Colorectal Cancer Treatments and Studies (17 papers), Cultural Competency in Health Care (14 papers), BRCA gene mutations in cancer (14 papers) and Gastric Cancer Management and Outcomes (12 papers). The work is most often cited by research in Oncology (13.5k citations), Gastroenterology (648 citations), Cancer Research (908 citations), Pulmonary and Respiratory Medicine (1.6k citations) and General Health Professions (1.1k citations). David Goldstein has collaborated with scholars based in Australia, United States and Canada. Frequent co-authors include Susanna B. Park, Michael Leonard Friedlander, Matthew C. Kiernan, Phyllis Noemi Butow, Arun V. Krishnan, Minoti Vivek Apte, Jeremy S. Wilson, Romano C. Pirola, Malcolm J. Moore and Cindy S.-Y. Lin. Their work appears in journals such as Annals of Oncology, Supportive Care in Cancer, Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact